Evaluation of novel aggregate structures as adjuvants: Composition, toxicity studies and humoral responses

Vaccine

Volumn 17, Issue 7-8, 1999, Pages 715-730

  Rajananthanan, Palasingam ^a   Attard, George S ^b   Sheikh, Nadeem A ^a   Morrow, W John W ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Amphiphile based adjuvants; Humoral responses; Toxicity studies

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; POLYMER; TOMATINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOPOTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; FEMALE; FREUND'S ADJUVANT; GLYCOLIPIDS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN M; ISCOMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; TOMATINE;

EID: 0033605353     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00256-4     Document Type: Article

References (46)

1. Audibert F., Lise L.D. Adjuvants: current status, clinical perspectives and future prospects. Immunology Today. 14:1993;281.
2. Sheikh N., Rajananthanan P., Morrow W.J.W. Immunological adjuvants: mechanisms of action and clinical application. Exp. Opin. Invest. Drugs. 5:1996;1079.
3. Alving C.R., Glass M., Detrick B. Summary: adjuvant/clinical trials working group. AIDS Res. Hum. Retroviruses. 8:1992;1427.
4. Hyslop N.S., Morrow A.W. The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines. Res. Vet. Sci. 10:1969;109.
5. Koff W.C., Glass M.J. Further direction in HIV vaccine development. AIDS Res. Human Retroviruses. 8:1992;1313.
6. Gupta R.K., Rost B.E., Relyveld E., Siber G. Adjuvant properties of aluminum and calcium compounds. In: Powell M.F., Newmandand M.K., editors. Vaccine design. New York: Plenum press, 1995. p. 229.
7. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumor antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 39:1980;435.
8. Morein B., Sundquist B., Hoglund S., Dalsgaard K., Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane protein from enveloped viruses. Nature. 308:1984;457.
9. Osterhaus A., Weijer K., Uytdehaag F., Jarrett O., Sundquist B., Morein B. Induction of protective immune response in cats by vaccination with feline leukaemia virus ISCOM. J. Immunol. 135:1985;591.
10. Morein B. The ISCOM antigen-presenting system. Nature. 332:1988;287.
11. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 334:1990;873.
12. Mowat A., Donachie A., Reid G., Jarrett O. Immune-stimulating complex containing Quil A protein antigen prime class I MHC-restricted T-lymphocytes in vivo and are immunogenic by the oral route. Immunology. 72:1991;317.
13. Newman M.J., Wu J.Y., Gardner B.H.et al. Saponin adjuvant induction of ovalbumin specific CD8+ cytotoxic T lymphocyte response. J. Immunol. 148:1992;2357.
14. Lockoff O. Glycolipids as immunomodulators: synthesis and properties. Angew. Chem. Intl. Edn. 30:1991;1611.
15. Attard G.S., Blackaby W.P., Leach A.R. The aggregation behavior of the two structurally isomeric glycolipids. Chem. Phys. Lipids. 74:1994;83.
16. Singh P., Moll F., Lin S.H.et al. Starburst dendrimers: enhanced performance and flexibility for immunoassays. Clin. Chem. 40:1994;1845.
17. Tam J.P. Immunization with peptide-carrier complexes: traditional and multiple-antigen peptide systems. In: Wisdom G.B., editor. Peptide antigen: a practical approach. Oxford: IRL press, 1994. p. 83-115.
18. Stewart-Tull D.E.S. Freund-type mineral oil adjuvant emulsions. In: Stewart-Tull D.E.S., editor. The theory and practical application of adjuvants. England: John Wiley and Sons, 1995. p. 1.
19. 3 and saponin is related to the immunogenicity of the antigen. Arch. Allerg. Appl. Immunol. 75:1984;280.
20. Morein B. The ISCOM: an immunostimulating system. Immunol. Lett. 25:1990;281.
21. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146:1991;431.
22. Edelman R., Tacket C.O. Adjuvants. Intern. Rev. Immunol. 7:1990;51.
23. Kenney J.S., Hughes B.W., Masada M.P., Allison A.C. Influence of adjuvants on the quantity, affinity, istotype and epitope specificity of murine antibodies. J. Immunol. Methods. 121:1989;157.
24. Karagouni E.E., Hadjipetrou-Kourounakis L. Regulation of istotype immunoglobulin production of adjuvants in vivo. Scand. J. Immunol. 41:1990;745.
25. Mosmann T.R., Coffman R.L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann. Rev. Immunol. 7:1989;145.
26. Grun J.L., Maurer P.H. Different T helper subsets elicited utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol. 121:1989;134.
27. Rajananthanan P., Attard G.S., Sheikh N.A., Morrow W.J.W. Novel aggregate structure adjuvants: induced cytokine profiles and proliferative responses. In preparation.
28. Sheikh N.A., van Rooijen N., Attard G.S., Rajananthanan P., Nye K.E., Morrow W.J.W. Targeting soluble protein into antigen presenting cell populations by delivery vehicles-induction of cytolytic T-cell responses. Submitted for publication.
29. Nicklas W. Aluminum salts. Res. Immunol. 143:1992;489.
30. Lindblad E.B. Aluminum adjuvants, In: Stewart-Tull D.E.S., editor. The theory and practical application of adjuvants. New York: John Wiley and Sons, 1995, p. 21.
31. Ramanathan V.D., Badenoch-Jones P., Turk J.L. Complement activation by aluminium and zirconium compounds. Immunology. 37:1979;881.
32. Raychaudhuri S., Tonks M., Carbone F.et al. Induction of antigen-specific class I-restricted cytotoxic T-cells by soluble protein in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;8308.
33. Hariharan K., Braslawsky G., Black A., Raychadhuri S., Hanna N. The induction of cytotoxic T-cells and tumor regression by soluble antigen formulation. Cancer Res. 55:1995;3486.
34. Souberbielle B.E., Knight B.C., Morrow W.J.W.et al. Comparison of IL-2 and IL4-transfected B16-F10 cells with a novel oil-microemulsion adjuvant for B16-F10 whole cell tumor vaccine. Gene Ther. 3:1996;853.
35. Allison A.C., Byars N.O. Immunological adjuvants and their mode of action. In: Ellis E.W., editor. Vaccines, new approaches to immunological problems. USA: Reed Publishing, 1992. p. 431-449.
36. Sheikh N., Rajananthanan P., Morrow W.J.W. Adjuvant-mediated antigen processing: a model for TAP independent processing. Immunology. 92 (Suppl. 1):1997;59.
37. Kukowska-Latallo J.F., Bielinska A.U., Johnson J., Spindler R.et al. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc. Natl. Acad. Sci. USA. 93:1996;4897.
38. Barth R.F., Adams D.M., Solway A.H., Alam F., Darby M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential system for neutron capture therapy. Bioconjugat. Chem. 5:1994;58.
39. Claassen I., Osterhaus A. The ISCOM structure as an immune-enhancing moiety: experience with viral systems. Res. Immunol. 143:1992;531.
40. Watson D.L., Watson N.A., Fossum C., Covgren K., Morein B. Interactions between immune-stimulating complex (ISCOMs) and peritoneal mononuclear leucocytes. Microbiol. Immunol. 36:1992;199.
41. Durand C., Pineau A., Bureau B., Stalder J.F. Complication cutanees des vaccinations diphterie, tetanos, coqueluche, polimyelite (tetracoq) role del'hydroxyde d'alumine. Nouv. Dermatol. 11:1992;523.
42. Yamanaka M., Hiramatsu K., Hirahara T.et al. Pathological studies on local tissue reactions in guinea pigs and rats caused by four different adjuvants. J. Vet. Med. Sci. 54:1992;685.
43. Kersten G.F., Spiekstra A., Beuvery E.C., Crommelin D.J. On the structure of immune-stimulating saponin-lipid complexes (ISCOMs). Biochim. Biophys. Acta. 102:1991;165.
44. Scott M.T., Goss-Sampson M., Bomford R. Adjuvant activity of saponin: antigen localization studies. Int. Arch. Allergy Appl. Immunol. 77:1985;409.
45. Romussi G., Cafaggis S., Bignardi G. Haemolytic action and surface activity of triterpene saponins from Anchusa offcinalis L. Part 21 on the Constituents of Boraginceae Pharmazie, 1980;35:498.
46. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) starburst dendrimers. J. Biomed. Mat. Res. 30:1996;53.